Safety and efficacy of (Absorb) Bioresorbable everolimus-eluting Vascular Scaffold in subjects with percutaneous chronic total occlusion

Trial Profile

Safety and efficacy of (Absorb) Bioresorbable everolimus-eluting Vascular Scaffold in subjects with percutaneous chronic total occlusion

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CTO ABSORB pilot
  • Most Recent Events

    • 19 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top